A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

NCT ID: NCT00486759

Last Updated: 2017-07-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 787 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-26
• Study Completion Date: 2011-11-30

Brief Summary

This 2-arm study was designed to compare the efficacy and safety of bevacizumab (Avastin) in combination with rituximab (MabThera) and CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) chemotherapy (R-CHOP) versus rituximab plus CHOP chemotherapy (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL). Patients were randomized to receive 8 cycles of treatment with R-CHOP plus bevacizumab or R-CHOP plus placebo. Treatment with bevacizumab/placebo and R-CHOP was given either on a 2-week or 3-week schedule and bevacizumab was given at a weekly average dose of 5 mg/kg (10 mg/kg for 2-week cycles and 15 mg/kg for 3-week cycles).

Detailed Description

An independent Data and Safety Monitoring Board (DSMB) was established to review safety data collected during the study on an ongoing basis. At its meeting in December 2009, the DSMB noted a trend for increased cardiac toxicity in the experimental arm (R-CHOP + bevacizumab) compared with the control arm (R-CHOP + placebo). Additional efficacy analyses of data from 720 randomized patients were presented at a DSMB meeting on May 22, 2010; they indicated no improvement in efficacy with the addition of bevacizumab to R-CHOP. It was noted, however, that there was an apparent increase in the risk of cardiotoxicity, premature treatment withdrawal, serious adverse events (SAEs), fatal adverse events (AEs), and perforation/ulcer in the experimental arm. Based on its assessment of an increased risk with unlikely benefit for patients randomized to the experimental arm, the DSMB recommended that further enrollment in the study be permanently halted and that bevacizumab be discontinued for any patients randomized to the experimental arm. On May 31, 2010, the sponsor took the decision to stop enrollment into the study and the bevacizumab treatment was terminated with immediate effect as recommended by the DSMB.

The study protocol was amended. The primary objective of the study was changed from evaluation of efficacy to evaluation of safety and the study was extended to include an 18-month safety follow-up period. Because enrollment was terminated prematurely resulting in fewer enrolled patients than planned, the outcome measure data are premature due to fewer than expected events.

The time frame for the reporting of serious adverse events was modified. Serious adverse events (SAE) unrelated to study treatment were reported until 1 year post-treatment or until new anti-lymphoma treatment was initiated. SAEs judged to be related to study treatment and congestive heart failure events were reported at any time during the study.

Conditions

B-cell Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Bevacizumab + rituximab + CHOP

Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).

Group Type: EXPERIMENTAL

Bevacizumab

Intervention Type: DRUG

Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Rituximab

Intervention Type: DRUG

Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

CHOP

Intervention Type: DRUG

Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Placebo + rituximab + CHOP

Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).

Group Type: ACTIVE_COMPARATOR

Rituximab

Intervention Type: DRUG

Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

CHOP

Intervention Type: DRUG

Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Placebo

Intervention Type: DRUG

Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Interventions

Bevacizumab

Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Intervention Type: DRUG

Rituximab

Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Intervention Type: DRUG

CHOP

Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Intervention Type: DRUG

Placebo

Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Intervention Type: DRUG

Other Intervention Names

Avastin; MabThera

Eligibility Criteria

Inclusion Criteria

• Adult patients, ≥ 18 and < 80 years of age.
• CD20-positive diffuse large B-cell lymphoma.
• Low-intermediate, high-intermediate, or high risk disease and/or bulky tumor (largest diameter ≥ 7.5 cm).
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

Exclusion Criteria

• Prior treatment for diffuse large B-cell lymphoma.
• Types of non-Hodgkin's lymphoma other than diffuse large B-cell lymphoma (DLBCL).
• Central nervous system (CNS) involvement of lymphoma.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Uni of California - San Diego; Cancer Center & Dept of Medicine

La Jolla, California, United States

Kenmar Research Inst.

Whittier, California, United States

University of Colorado Cancer Center Department of Hematology

Aurora, Colorado, United States

Uni Medical Center; Division Of Hemotology/Oncology

Jacksonville, Florida, United States

Florida Cancer Specialists

West Palm Beach, Florida, United States

Northwest Georgia Oncology Centers

Marietta, Georgia, United States

University of Kansas Medical Center; Department of Hematology

Kansas City, Kansas, United States

St. Joseph Mercy Hospital; Department of Oncology

Ann Arbor, Michigan, United States

Northeast Oncology Associates

Concord, North Carolina, United States

Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates

Winston-Salem, North Carolina, United States

Providence Portland Medical Center

Portland, Oregon, United States

Charleston Cancer Center

Charleston, South Carolina, United States

Uni of Texas Southwestern Medical Center

Dallas, Texas, United States

Cancer Therapy & Research Center

San Antonio, Texas, United States

Northwest Medical Specialties B

Federal Way, Washington, United States

Rainier Physicians

Puyallup, Washington, United States

Northwest Medical Specialties

Tacoma, Washington, United States

Hospital Italiano; Haemathology

Buenos Aires, , Argentina

Fundaleu; Haematology

Buenos Aires, , Argentina

Hospital Britanico; Haematology

Buenos Aires, , Argentina

HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología

Córdoba, , Argentina

Greenslopes Private Hospital; Gallipoli Research Centre

Greenslopes, Queensland, Australia

Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology

Woolloongabba, Queensland, Australia

Royal Adelaide Hospital; Haematology, Institute of Medical Veterinary Science

Adelaide, South Australia, Australia

Ashford Cancer Center Research

Kurralta Park, South Australia, Australia

Frankston Hospital; Oncology/Haematology

Frankston, Victoria, Australia

Peter Maccallum Cancer Institute; Medical Oncology

Melbourne, Victoria, Australia

Alfred Hospital; Bone Marrow Transplant Unit

Melbourne, Victoria, Australia

Border Medical Oncology; Murray Valley Private Hospital

Wodonga, Victoria, Australia

Fremantle Hospital; Haematology

Fremantle, Western Australia, Australia

Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I

Graz, , Austria

Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.

Salzburg, , Austria

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie

Vienna, , Austria

Centro Goiano de Oncologia - CGO

Goiânia, Goiás, Brazil

Hospital de Caridade de Ijui; Oncologia

Ijuí, Rio Grande do Sul, Brazil

Hospital das Clinicas - UFRGS; Hematologia

Porto Alegre, Rio Grande do Sul, Brazil

Hospital Nossa Senhora da Conceicao

Porto Alegre, Rio Grande do Sul, Brazil

Hospital das Clinicas - UNICAMP

Campinas, São Paulo, Brazil

Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia

Santo André, São Paulo, Brazil

Santa Casa de Misericordia de Sao Paulo; Hematologia e Hemoterapia

São Paulo, São Paulo, Brazil

Hospital das Clinicas - FMUSP; Hematologia

São Paulo, São Paulo, Brazil

Tom Baker Cancer Centre; Dept of Medicine

Calgary, Alberta, Canada

Cross Cancer Institute ; Dept of Medical Oncology

Edmonton, Alberta, Canada

Cancer Care Manitoba

Winnipeg, Manitoba, Canada

Moncton Hospital

Moncton, New Brunswick, Canada

Health Science Centre

St. John's, Newfoundland and Labrador, Canada

QEII HSC; Oncology

Halifax, Nova Scotia, Canada

Cancer Centre of Southeastern Ontario; Kingston General Hospital

Kingston, Ontario, Canada

Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre

Mississauga, Ontario, Canada

Toronto Sunnybrook Regional Cancer Centre

Toronto, Ontario, Canada

University Health Network; Princess Margaret Hospital; Medical Oncology Dept

Toronto, Ontario, Canada

Windsor Regional Cancer Centre

Windsor, Ontario, Canada

Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie

Greenfield Park, Quebec, Canada

Mcgill University - Royal Victoria Hospital; Oncology

Montreal, Quebec, Canada

McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology

Montreal, Quebec, Canada

Hopital de L'Enfant-Jesus; Hematology

Québec, Quebec, Canada

Chuq - Hopital Hotel Dieu de Quebec; Oncology

Québec, Quebec, Canada

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada

Saskatoon Cancer Centre; Uni of Saskatoon Campus

Saskatoon, Saskatchewan, Canada

Cancer Hospital Chinese Academy of Medical Sciences.

Beijing, , China

Beijing Cancer Hospital

Beijing, , China

Beijing Union Hospital

Beijing, , China

General Hospital of Chinese PLA; Department of Hematology

Beijing, , China

Fujian Cancer Hospital

Fuzhou, , China

Fudan University Shanghai Cancer Center

Shanghai, , China

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Changhai Hospital of Shanghai

Shanghai, , China

The Second Affiliated Hospital of Soochow University

Suzhou, , China

First Affiliated Hospital of Soochow University

Suzhou, , China

Tianjin Institute of Hematology & Blood Diseases Hospital

Tianjin, , China

The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)

Xi'an, , China

Organizacion Sanitas Internacional

Bogotá, , Colombia

Hospital Pablo Tobon Uribe

Medellin-Antioquia, , Colombia

Instituto Cancerologia Medellin; Clinica Las Americas

Medellín, , Colombia

Oncólogos de Occidente

Pereira, , Colombia

Fakultni nemocnice Brno; Interni hematoonkologicka klinika

Brno, , Czechia

Fn Hr. Kralove; IV. Interni Hematologicka Klinika

Hradec Králové, , Czechia

Fakultni nemocnice Olomouc; Hemato-onkologicka klinika

Olomouc, , Czechia

Fakultni Nemocnice Plzen, Hematologicko-Onkologicke Oddeleni

Plzen - Lochotin, , Czechia

Fakultní Nemocnice Královské Vinohrady; Hematologická Klinika

Prague, , Czechia

VshEOBECNÁ FAKULTNÍ NEMOCNICE; I. INTERNI KLINIKA

Prague, , Czechia

Teodoro Maldonado Carbo Hospital; Oncology Service

Guayaquil, , Ecuador

Hospital Carlos Andrade Marin; Servicio de Oncología

Quito, , Ecuador

Hospital Solca Quito; Oncologia

Quito, , Ecuador

Clinique Claude Bernard; Onco Hematologie

Albi, , France

Centre Hospitalier Uni Ire; Service de Medecine D

Angers, , France

Institut Bergonie; Hematologie Oncologie

Bordeaux, , France

Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie

Bordeaux, , France

Centre Francois Baclesse; Comite 2

Caen, , France

Chu Estaing; Cons Hemato Medecine Interne

Clermont-Ferrand, , France

Chu Site Du Bocage;Hematologie Clinique

Dijon, , France

CH Dptal Les Oudairies; Hematologie Oncologie

La Roche-sur-Yon, , France

Hopital Albert Michallon; Oncologie

La Tronche, , France

Clinique Victor Hugo; Chimiotherapie

Le Mans, , France

Hopital Claude Huriez; Hematologie

Lille, , France

Hopital Uni Ire Dupuytren; Hematologie

Limoges, , France

Centre Leon Berard; Departement Oncologie Medicale

Lyon, , France

Institut J Paolii Calmettes; Onco Hematologie 1

Marseille, , France

Clinique Pont de Chaume; Oncologie Et Radiotherapie

Montauban, , France

Hopital Saint Eloi; Hematologie Oncologie Medicale

Montpellier, , France

Hopital de L'Archet; Hematologie Clinique

Nice, , France

Polyclinique Kenval ; Radiotherapie Oncologie

Nîmes, , France

Institut Curie; Oncologie Medicale

Paris, , France

Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)

Paris, , France

Hopital Pitie Salpetriere; Hematologie Clinique

Paris, , France

Hopital Saint Jean; Hematologie

Perpignan, , France

Hopital De Haut Leveque; Hematologie Clinique

Pessac, , France

Ch Lyon Sud; Hemato Secteur Jules Courmont

Pierre-Bénite, , France

Hopital De La Miletrie; Hematologie Et Oncologie Medicale

Poitiers, , France

Ch Jacques Puel;Oncologie Medicale

Rodez, , France

ICL; Hematologie

Saint-Priest-en-Jarez, , France

Hopital Sud; Hematologie Clinique

Salouël, , France

Hopital Purpan; Hematologie Clinique

Toulouse, , France

Clinique Pasteur; Oncologie Medicale

Toulouse, , France

Hopital Bretonneau; Hematologie Therapie Cellulaire

Tours, , France

Hopitaux De Brabois; Hematologie Medecine Interne

Vandœuvre-lès-Nancy, , France

Institut Gustave Roussy; Unite D'Hematologie

Villejuif, , France

Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie

Amberg, , Germany

Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.

Berlin, , Germany

Charité; Onkologie & Hämatologie

Berlin, , Germany

DIAKO Ev. Diakonie-Krankenhaus Bremen GmbH; Med. Klinik II; Hämatologie und internistische Onkologie

Bremen, , Germany

Carl-Thiem-Klinik Cottbus; Medizinische Klinik

Cottbus, , Germany

Klinikzentrum Mitte; Medizinische Klinik Gastroenterologie Haematologie / Onkologie

Dortmund, , Germany

St. Johannes Hospital; Abt. Innere Medizin

Dortmund, , Germany

St Antonius Hospital; Haematologie/Onkologie

Eschweiler, , Germany

Krankenhaus Nordwest Medizinische Klinik

Frankfurt, , Germany

Klinik Fulda; Abt. Itz

Fulda, , Germany

Georg-August-Uniklinik ; Zentrum Innere Medizin Abt. Hämatologie & Onkologie

Göttingen, , Germany

Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik

Greifswald, , Germany

Kath.Krankenhaus Hagen gem.GmbH St.-Marien-Hospital

Hagen, , Germany

Asklepios Klinik St. Georg; Allgemeine Innere Medizin

Hamburg, , Germany

Facharztzentrum Eppendorf, Studien GbR

Hamburg, , Germany

Evang.Krankenhaus Abt. Hämatologie und Onkologie

Hamm, , Germany

St.-Marien-Hospital Klinik Knappenstraße; Klinik für Hämatologie und Onkologie

Hamm, , Germany

KRH Klinikum Siloah Medizinische Klinik III

Hanover, , Germany

St. Bernward-Krankenhaus

Hildesheim, , Germany

Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I

Homburg/Saar, , Germany

Städtisches Klinikum Karlsruhe gGmbH, II. Medizinische Klinik

Karlsruhe, , Germany

St. Vincentius Kliniken Ag; Medizinische Klinik Abt. 2

Karlsruhe, , Germany

Tagesklinik Landshut; Hämatologie/Onkologie

Landshut, , Germany

Universitätsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog.

Leipzig, , Germany

Klinikum St.Georg gGmbH Klinik für Internistische Onkologie und Hämotologie

Leipzig, , Germany

Klinikum der Stadt Ludwigshafen; Medizinische Klinik A

Ludwigshafen, , Germany

Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Med. Klinik I, Hämatologie/Onkologie

Lübeck, , Germany

Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie

Lüdenscheid, , Germany

Otto von Guericke Uni Magdeburg Uniklinik; Hämatologie/Onkologie

Magdeburg, , Germany

Klinikum Magdeburg gemeinnützige GmbH; Klinik Haematologie und Onkologie

Magdeburg, , Germany

Klinikum Mannheim III. Medizinische Klinik

Mannheim, , Germany

Klinikum der Universitaet Muenchen; Campus Großhadern; Medizinische Klinik III und Poliklinik

München, , Germany

Westfälische Wilhelms-Universität Münster, Medizinische Klinik und Poliklinik A

Münster, , Germany

Klinikum Oldenburg gGmbH; Klinik für Onkologie und Hämatologie

Oldenburg, , Germany

Prosper-Hospital, Medizinische Klinik I

Recklinghausen, , Germany

St Marien Krankenhaus; Medizinische Klinik Iii

Siegen, , Germany

Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie

Trier, , Germany

Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie

Trier, , Germany

Eberhard-Karls-Universität Tübingen; Medizinische Klinik I

Tübingen, , Germany

Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.

Ulm, , Germany

HSK Dr.-Horst-Schmidt-Kliniken; Innere Medizin I Kardiologie; Angiologie und Intensivmedizin

Wiesbaden, , Germany

Helios Klinik Wuppertal; Medizinische Klinik I

Wuppertal, , Germany

Kliniken St. Antonius; Zentrum Für Innere Medizin, Haematologie/Onkologie

Wuppertal, , Germany

Georgios Papanikolaou Hospital; Hematology Department

Thessaloniki, , Greece

Queen Elizabeth Hospital; Clinical Oncology

Hong Kong, , Hong Kong

Queen Mary Hospital; Dept of Medicine

Hong Kong, , Hong Kong

Fov. Onk. Egyesitett Szent Istvan es Szent Laszlo Korhaz; Dept Of Bone Marrow Transplant

Budapest, , Hungary

National Institute of Oncology, A Dept of Internal Medicine

Budapest, , Hungary

University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology

Debrecen, , Hungary

Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica

Bari, Apulia, Italy

A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna

Bologna, Emilia-Romagna, Italy

Ospedale Regionale Di Parma; Divisione Di Oncologia Medica

Parma, Emilia-Romagna, Italy

Az. Osp. Arcispedale S. Maria Nuova; U.O. Di Ematologia

Reggio Emilia, Emilia-Romagna, Italy

Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica

Aviano, Friuli Venezia Giulia, Italy

A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica

Udine, Friuli Venezia Giulia, Italy

Univ. Cattolica La Sapienza; Cattedra Di Ematologia

Rome, Lazio, Italy

ASST DI MONZA; Ematologia

Monza, Lombardy, Italy

Irccs Policlinico San Matteo; Divisione Di Ematologia

Pavia, Lombardy, Italy

Università Cattolica Del Sacro Cuore S.S. Giovanni Paolo Ii; Uoc Di Onco-Ematologia

Campobasso, Molise, Italy

Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico

Orbassano, Piedmont, Italy

A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1

Turin, Piedmont, Italy

Ospedale Ferrarotto; Divisione Di Ematologia

Via S. Sofia 78, Sicily, Italy

Ospedale Gen.Le Prov.Le 'C.G.Mazzoni'; Ematologia

Ascoli Piceno, The Marches, Italy

Ospedale Santa Chiara; Unita Operativa Di Ematologia

Pisa, Tuscany, Italy

Seamen' Hospital' Dept. of haematology

Klaipėda, , Lithuania

Uni Hospital Santariskiu Clinic; Haematology

Vilnius, , Lithuania

Hospital Pulau Pinang

George Town, Pulau Pinang, Malaysia

Instituto Biomedico De Investigacion A.C.

Aguascalientes, , Mexico

Hospital Español; Hematología Sala 19

Mexico City, , Mexico

Col Instituto Tecnologico Y Estudios Superiores de Monterrey

Monterrey, , Mexico

Hospital Universitario Dr. Jose E. Gonzalez; Haematology

Monterrey, , Mexico

North Shore Hospital; Haematolgy

Auckland, , New Zealand

Uni of Auckland; Dept of Molecular Medicine & Haematology

Auckland, , New Zealand

Christchurch Hospital; Canterbury Health Laboratories

Christchurch, , New Zealand

Centro Hemato Oncologico Paitilla

Panama City, , Panama

Hospital Nacional Almanzor Aguinaga Asenjo; Unidad De Investigacion Del Servicio De Oncologia Medica

Chiclayo, , Peru

Hospital Nacional Edgardo Rebagliati Martins; Oncologia

Lima, , Peru

Hospital Nacional Guillermo Almenara Irigoyen; Oncology

Lima, , Peru

Instituto Nacional de Enfermedades Neoplasicas

Lima, , Peru

Hospital Nacional LNS dela Policia Nacional del Perú. Unidad Onco; Deapartamento de Oncología

Lima, , Peru

Cebu Cancer Institute; Perpetual Succour Hospital

Cebu, , Philippines

National Kidney and Transplant Institute; Chemotherapy Unit

Diliman, Quezon City, , Philippines

St Luke'S Medical Centre; Oncology

Quezon City, , Philippines

Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny

Brzozów, , Poland

Szpital Uniwersytecki W Krakowie; Klinika Hematologii

Krakow, , Poland

Medical University School; Dept. of Haematology

Lodz, , Poland

Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie

Lublin, , Poland

Zaklad Opieki Zdrowotnej Mswia; Oddzial Chemioterapii

Olsztyn, , Poland

Samodzielny Publiczny Centralny Szpital Kliniczny; Haematology Dept.

Warsaw, , Poland

Centralny Szpital Kliniczny Mswia; Klinika onkologii, hematologii i chorob wewnetrznych

Warsaw, , Poland

Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Lymphoma Dept.

Warsaw, , Poland

HUC; Servico de Hematologia

Coimbra, , Portugal

IPO de Lisboa; Servico de Hematologia

Lisbon, , Portugal

Hospital de Sao Joao; Servico de Hematologia Clinica

Porto, , Portugal

Republican Clinical Oncologic Dispensary of Republic Of Tatarstan

Kazan', , Russia

N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis

Moscow, , Russia

Haematology Research Center; Haematology

Moscow, , Russia

Semashko Central Clinical Hospital Moscow; Hematology

Moscow, , Russia

Research Inst. of Hematology & Blood Transfusion ; Hematology

Saint Petersburg, , Russia

National Cancer Inst. ; Dept. of Chemotherapy

Bratislava, , Slovakia

Samsung Medical Centre; Oncology

Seoul, , South Korea

Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology

Seoul, , South Korea

Korean Cancer Center Hospital; Oncology

Seoul, , South Korea

Severance Hospital - Yonsei University; Medicine Dept.

Seoul, , South Korea

Hospital Mutua de Terrassa; Servicio de Hematologia

Terrassa, Barcelona, Spain

Hospital Universitario Marques de Valdecilla; Servicio de Hematologia

Santander, Cantabria, Spain

Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia

A Coruña, La Coruña, Spain

Hospital Universitario de Canarias;servicio de Oncologia

San Cristóbal de La Laguna, Tenerife, Spain

Hospital de Basurto; Servicio de Hematologia

Bilbao, Vizcaya, Spain

Hospital de Galdakano

Galdakano, Vizcaya, Spain

Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia

Barcelona, , Spain

Hospital Universitari Vall d'Hebron; Servicio de Hematologia

Barcelona, , Spain

Hospital Clínic i Provincial; Servicio de Hematología y Oncología

Barcelona, , Spain

Hospital Duran i Reynals; Servicio de Hematologia

Barcelona, , Spain

Complejo Hospitalario de Jaen- Hospital Universitario Medico Quirurgico; Servicio de Hematologia

Jaén, , Spain

Hospital Universitario Clínico San Carlos; Servicio de Hematología

Madrid, , Spain

Hospital Universitario la Paz; Servicio de Hematologia

Madrid, , Spain

Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia

Málaga, , Spain

Hospital Clinico Universitario de Salamanca;Servicio de Hematologia

Salamanca, , Spain

Hospital Universitario Virgen del Rocio; Servicio de Hematologia

Seville, , Spain

Hospital Universitario la Fe; Servicio de Medicina Intena

Valencia, , Spain

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

Valencia, , Spain

Hospital Universitario Miguel Servet; Servicio Hematologia

Zaragoza, , Spain

Skånes University Hospital, Skånes Department of Onclology

Lund, , Sweden

Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling

Malmo, , Sweden

Länssjukhuset; Medicinkliniken

Sundsvall, , Sweden

Akademiska sjukhuset, Onkologkliniken

Uppsala, , Sweden

Universitätsspital Zürich; Klinik für Onkologie

Zurich, , Switzerland

Veterans General Hospital; Division of Oncology

Taipei, , Taiwan

Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology

Taipei, , Taiwan

Chang Gung Medical Foundation-Taipei

Taoyuan District, , Taiwan

King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine

Bangkok, , Thailand

National Cancer Inst.

Bangkok, , Thailand

Rajavithi Hospital; Medicine

Bangkok, , Thailand

Siriraj Hospital; Division of Hematology, Department of Medicine

Bangkok, , Thailand

Chiang Mai Uni Hospital; Division of Hematology,Dept of Medicine,Faculty of Medicine

Chiang Mai, , Thailand

Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine

Khon Kaen, , Thailand

Birmingham Heartlands Hospital; Department of Haematology

Birmingham, , United Kingdom

Bradford Royal Infirmary; Haematology Department

Bradford, , United Kingdom

North Hampshire Hospital; Dept. of Haematology

Hampshire, , United Kingdom

Princess Alexandra Hospital; Department of Haematology

Harlow, , United Kingdom

Leicester Royal Infirmary; Dept. of Medical Oncology

Leicester, , United Kingdom

Royal Liverpool Uni Hospital; Haematology

Liverpool, , United Kingdom

St. George'S Hospital; Haematology

London, , United Kingdom

Hillingdon Hospital

Middx, , United Kingdom

Churchill Hospital; Oxford Cancer and Haematology Centre

Oxford, , United Kingdom

Royal Hallamshire Hospital; Haematology Dept

Sheffield, , United Kingdom

Weston Park Hospital; Cancer Clinical Trials Centre

Sheffield, , United Kingdom

The Royal Wolverhampton Hospitals NHS Trust; Department of Haematology

Wolverhampton, , United Kingdom

Countries

United States; Argentina; Australia; Austria; Brazil; Canada; China; Colombia; Czechia; Ecuador; France; Germany; Greece; Hong Kong; Hungary; Italy; Lithuania; Malaysia; Mexico; New Zealand; Panama; Peru; Philippines; Poland; Portugal; Russia; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; United Kingdom

References

McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, Sehn LH, Venstrom JM. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019 Feb 26;3(4):531-540. doi: 10.1182/bloodadvances.2018020602.

Reference Type: DERIVED

PMID: 30770362 (View on PubMed)

Seymour JF, Pfreundschuh M, Trneny M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B; MAIN Study Investigators. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014 Aug;99(8):1343-9. doi: 10.3324/haematol.2013.100818. Epub 2014 Jun 3.

Reference Type: DERIVED

PMID: 24895339 (View on PubMed)

Other Identifiers

BO20603

Identifier Type: -

Identifier Source: org_study_id